Round robin test on quantification of amyloid‐β 1–42 in cerebrospinal fluid by mass spectrometry. Issue 1 (20th July 2015)

• Record Type: Journal Article
• Authors: Pannee, Josef; Gobom, Johan; Shaw, Leslie M.; Korecka, Magdalena; Chambers, Erin E.; Lame, Mary; Jenkins, Rand; Mylott, William; Carrillo, Maria C.; Zegers, Ingrid; Zetterberg, Henrik; Blennow, Kaj; Portelius, Erik
• Is Part Of: Alzheimer's & dementia. Volume 12:Issue 1(2016)
• Page Start: 55
• Page End: 59
• Publication Date: 2015-07-20
• Subjects: Amyloid beta -- Cerebrospinal fluid -- Mass spectrometry -- Interlaboratory study; Alzheimer's disease -- Periodicals; Alzheimer Disease -- Periodicals; Dementia -- Periodicals; Démence; Maladie d'Alzheimer; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.83
• DOI: 10.1016/j.jalz.2015.06.1890
• Languages: English
• ISSNs: 1552-5260

Abstract

Abstract: Introduction: Cerebrospinal fluid (CSF) amyloid‐β 1–42 (Aβ42 ) is an important biomarker for Alzheimer's disease, both in diagnostics and to monitor disease‐modifying therapies. However, there is a great need for standardization of methods used for quantification. To overcome problems associated with immunoassays, liquid chromatography‐tandem mass spectrometry (LC‐MS/MS) has emerged as a critical orthogonal alternative. Methods: We compared results for CSF Aβ42 quantification in a round robin study performed in four laboratories using similar sample preparation methods and LC‐MS instrumentation. Results: The LC‐MS results showed excellent correlation between laboratories ( r 2 >0.98), high analytical precision, and good correlation with enzyme‐linked immunosorbent assay ( r 2 >0.85). The use of a common reference sample further decreased interlaboratory variation. Discussion: Our results indicate that LC‐MS is suitable for absolute quantification of Aβ42 in CSF and highlight the importance of developing a certified reference material.